Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 9/20 | 0.65 |
| ▸ | APP | P05067 | 1/20 | 0.62 |
| ▸ | CETP | P11597 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.44 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.44 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19838236 | 0.98 | SELP (0.62) | SELPAPPCETPTP53CYP1A2 | |
| SCHEMBL16084109 | 0.94 | CETP (0.69) | SELPAPPCETPTP53CYP1A2 | |
| SCHEMBL29392451 | 0.94 | SELP (0.60) | SELPAPPCETPTP53CYP1A2 | |
| SCHEMBL29351275 | 0.93 | SELP (0.57) | SELPAPPCETPTP53CYP1A2 | |
| SCHEMBL12563518 | 0.92 | SELP (0.77) | SELPAPPCETP | |
| SCHEMBL30653862 | 0.92 | SELP (0.77) | SELPAPPCETP | |
| SCHEMBL9359220 | 0.92 | SELP (0.77) | SELPAPPCETP | |
| SCHEMBL30842632 | 0.92 | SELP (0.77) | SELPAPPCETP | |
| SCHEMBL9362810 | 0.92 | SELP (0.77) | SELPAPPCETP | |
| SCHEMBL29362094 | 0.92 | SELP (0.77) | SELPAPPCETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2783 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630114-B9 | MIGALASTAT FOR TREATING FABRY PATIENTS HAVING RENAL IMPAIRMENT | AMICUS THERAPEUTICS INC (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4743115-A2 | MULTISPECIFIC ANTIBODIES AND USES THEREOF | LTZ Therapeutics Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| US-12599595-B2 | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones | AMICUS THERAPEUTICS, INC. (US) | 2026-04-14 | — | — | US | claimed |
| US-12599594-B2 | Treatment of Fabry disease in ERT-naïve and ERT-experienced patients | AMICUS THERAPEUTICS, INC. (US) | 2026-04-14 | — | — | US | claimed |
| EP-4713370-A2 | ANTIBODIES AND USES THEREOF | LTZ Therapeutics Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| EP-4577249-A1 | COMPOSITION FOR USE IN THE TREATMENT OF FABRY DISEASE | Takeda Pharmaceutical Company Limited (JP) | 2025-07-02 | — | — | EP | claimed |
| US-20250207118-A1 | HUMAN ALPHA-GALACTOSIDASE VARIANTS | CODEXIS, INC. | 2025-06-26 | — | — | US | claimed |
| US-20250179460-A1 | HUMAN ALPHA-GALACTOSIDASE VARIANTS | CODEXIS, INC. | 2025-06-05 | — | — | US | claimed |
| US-20250177572-A1 | COMPOSITION FOR USE IN THE TREATMENT OF FABRY DISEASE | TAKEDA PHARMACEUTICALS CO (JP) | 2025-06-05 | — | — | US | claimed |
| US-20250144240-A1 | METHODS FOR USE OF VIRAL VECTOR CONSTRUCTS FOR THE TREATMENT OF FABRY DISEASE | SANGAMO THERAPEUTICS INC (US) | 2025-05-08 | — | — | US | claimed |
| US-6084092-A | ISOLATING BETA-GLUCANS BY CONTACTING SAMPLE WITH GLYCOSPHINGOLIPID WHICH BINDS TO GLUCANS, ISOLATING THE COMPLEXES, AND ISOLATING BETA-GLUCAN FROM THE COMPLEXES; FOR ACCURATE, SENSITIVE, SIMPLE DETECTION OF FUNGAL INFECTIONS | THE COLLABORATIVE GROUP, LTD. (US) | 2000-07-04 | — | — | US | claimed |
| WO-2000029556-A2 | IDENTIFICATION OF GLYCOSPHINGOLIPIDS THAT PROMOTE HIV-1 ENTRY INTO CELLS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2000-05-25 | — | — | WO | claimed |
| US-5955293-A | IMMUNOASSAY BY CONTACTING SAMPLE WITH CAPTURE AGENT BOUND TO SOLID SUPPORT, THEN WITH MONOCLONAL ANTIBODY, DETECTING PRESENCE OR ABSENCE OF BINDING | NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. (US) | 1999-09-21 | — | — | US | claimed |
| WO-1999038530-A1 | AGENT CAPABLE OF MODULATING A GLYCOSPHINGOLIPID-ASSOCIATED ACTIVITY THUS AFFECTING AN IMMUNE DISORDER | UNIVERSITY OF BRISTOL (GB) | 1999-08-05 | — | — | WO | claimed |
| WO-1999031510-A1 | β(1-3)-GLUCAN DIAGNOSTIC ASSAYS | THE COLLABORATIVE GROUP, LTD. (US) | 1999-06-24 | — | — | WO | claimed |
| WO-1998035233-A1 | RECEPTOR-BASED ASSAYS FOR PATHOGENS | THE JOHNS HOPKINS UNIVERSITY (US) | 1998-08-13 | — | — | WO | claimed |
| EP-0130132-A1 | Antitumour immunotoxin, pharmaceutical compositions containing it, and its use in vitro | Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 1985-01-02 | — | — | EP | claimed |
| US-4464360-A | UROGENITAL DISORDERS | LEFFLER HAKON (SE) | 1984-08-07 | — | — | US | claimed |
| EP-0058665-A1 | CARBOHYDRATE DERIVATIVES FOR INHIBITING BACTERIAL ADHERENCE. | LEFFLER HAKON (SE) | 1982-09-01 | — | — | EP | claimed |
| WO-1981003175-A1 | CARBOHYDRATE DERIVATIVES FOR INHIBITING BACTERIAL ADHERENCE | LEFFLER H | 1981-11-12 | — | — | WO | claimed |